PATENT CLAIM ANALYSIS

Application Number: 16415319
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-09
Patent Classification: ["514", "230500"]

Abstract:
The present invention relates to novel compounds or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions and treatment methods or uses as antibacterials for bacterial infections.

Claim (Index 36):
The method of  claim 35 , wherein the bacterial infection is caused by one or more organisms selected from the group consisting of  Haemophilus influenza, Moraxella catarrhalis, Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Legionella pneumonia, Stenotrophomonas maltophilla , the  Citrobacter  genus,  Burkholderia cepacian, Serratia marcescens, Providencia rettgeri, Staphylcoccus aureus, Streptococcus pneumoniae, Streptococcus pyrogenes, Streptococcus agalactiae, Enterococcus faecalis, Enterococcus faecium , methicillin resistant  Staphylococcus aureus  (MRSA), and anaerobic bacteria of the genus  Bacteroides.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 100.0
- Lexical Diversity: 1.03846
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12298326', '12809555', '10502233', '12520580', '12279329']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8156530996702582
- 35 USC 102 Novelty (BERT): 0.5430776549597328
- Combined Prediction Score: 0.7883955551992057
- Mean Citation Score: 366.715636
- Max Citation Score: 386.1195
- Similarity Product: 271.38974603319167

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test